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Abstract
Focal adhesion kinase (FAK) is a cytoplasmic non-receptor tyrosine kinase essential for a diverse 
set of cellular functions. Current methods for monitoring FAK activity in response to extracellular 
stimulus lack spatiotemporal resolution and/or the ability to perform multiplex detection. Here we 
report on a novel approach to monitor real-time kinase phosphorylation activity of FAK in live 
single cells by fluorescence lifetime imaging.
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An increasing body of evidence1–3 reveals that cells are very sensitive to extracellular 
mechanical cues. Mechanical signaling within a tissue is crucial for tensional homeostasis 
between and within cells, modulating a repertoire of cellular processes, such as 
differentiation4, development5, and survival6. Focal adhesion kinase (FAK) is a cytoplasmic 
non-receptor tyrosine kinase that is essential for diverse cellular function, especially cell 
motility, adhesion and migration7. FAK controls cell motility through its complex 
multifaceted molecular connections that regulate the dynamic interplay between cellular 
actin cytoskeleton, cell membrane protrusion8, and cell adhesion site with the extracellular 
matrix (or substrate). More importantly, FAK serves as a receptor-proximal regulator of cell 
movement, by transducing extracellular signals that ultimately govern cell motility9. FAK 
phosphorylation plays a pivotal role in transmitting extracellular cues, including mechanical 
tension, to a variety of intracellular targets. Regulation of FAK phosphorylation activity 
hence warrants specific cellular response to extracellular stimulation. Abnormal FAK 
activity has been implicated in malignancies such as angiogenesis-dependent diseases10, 
developmental disorders11, tumor progression and metastasis12, and neurological disorder13. 
Small molecule inhibitors14, 15 have been developed to inhibit FAK activities, resulting in 
inhibited angiogenesis16 or cell migration17 during tumor progression or other disease 
pathogenesis.
Understanding FAK signaling dynamics will help to address fundamental and applied 
questions in the field of biotechnology, medical biology, and drug development. FAK 
activation due to perturbation by a stimulii from extracellular matrix effects, growth factors, 
or drugs is a rapid, dynamic and a highly evolving process. Current methods18,19 for 
monitoring FAK phosphorylation activity predominantly use cell lysate or utilize genetically 
encoded sensors. A major drawback in phosphorylation monitoring using cell lysate is the 
loss of spatiotemporal information which is pivotal in intracellular signal transduction from 
environmental cues to downstream signaling protein. Although, real time monitoring can be 
achieved with genetically modified sensors, ease and feasibility of developing a stable 
transfection across different cell lines limit its application especially in cell lines derived 
from patient tumor. Moreover, genetically encoded sensors are limited in their ability to 
probe multiple pathways. Herein we report on a novel approach to monitor FAK signaling in 
live cells by measuring the real-time kinase phosphorylation activity of FAK. We utilized 
Time-Correlated Single Photon Counting (TCSPC) Fluorescence Lifetime Imaging 
(FLIM)18–23 to monitor FAK phosphorylation with a FAK peptide biosensor (FAKSOR) as 
depicted in Figure 2. Our design exploits the auto phosphorylation property of FAK at 
Tyr397 sites, used as the recognition motif (Fig. 2e) of the sensor.
A putative peptide substrate containing the Tyr397 phosphorylation site and its adjacent 
amino acid (Fig. 2e red), which serves as the sensors’ recognition sequence (Fig 2e. sensor 
dark blue part) was designed. Cellular FAK will identify the putative sequences in the 
biosensor and phosphorylate the Tyrosine (Tyr 397 residue).
Additionally, to facilitate live cell monitoring, we incorporate a cell-penetrating peptide 
sequence in the FAKSOR design (Fig. 2e. sensor light blue part). For signal reporting, 5-
FAM (Ex/Em 492/518) fluorophore was conjugated to the lysine residue, two amino acids 
from the Tyr397 phosphorylation site (Fig. 2e). The working principle of FAKSOR is as 
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follows: upon phosphorylation of the peptide sensor at the Tyr397 site by the cellular FAK, 
the phospho group in the FAKSOR (phopsho-Tyr) conforms to bind with the cellular 
phospho-binding domain of the kinase to alter the fluorescence lifetime of 5-FAM in a 
kinase phosphorylation dependent manner(Fig. 2a–d) due to a change in the solvatochromic 
microenvironment upon phosphorylation23.
A challenge with genetically encoded or nanoparticle-based sensors is the lack of uniform 
uptake by different cell lines24, 25. The efficacy of cellular delivery of the FAKSOR was 
tested in five different cell lines (ESI Fig. 6). FAKSOR was rapidly internalized by the cells 
within 20 minutes of incubation with the biosensor. To validate subcellular localization, cells 
were stained via immunofluorescence and visualized with confocal microscopy (ESI Fig. 7). 
In concordance with the FLIM image, immunostaining demonstrates two subcellular 
localizations of FAK; 1) cytoplasmic localization marked with punctate cytoplasmic 
sturcture and focal adhesion occupancy, and 2) nuclear localization. These observations are 
in agreement with previous studies reporting on FAK cytoplasmic8 and nuclear location26.
To assess specificity of FAKSOR and demonstrate FAK kinase phosphorylation dependant 
fluorescence lifetime shift, a FAK-specific small molecule activator (Angiotensin II), was 
utilized as the positive control, and tested in the three different cell types. After pretreatment 
of cells with Angiotensin II for 1 hour, the fluorescence lifetime of the internalized 
FAKSOR recorded was found to be greater than the untreated control (Fig. 3, ESI Fig. 8, 9). 
Two negative controls were tested: 1) an FAK-specific inhibitor (FI-14) and 2) a non-
phosphorylatable mutant FAKSOR peptide (Fig. 3, ESI Fig. 3 a, b). Compared to 
Angiotensin II-stimulated cells (Fig. 3a, d, e; 3.9 ns), negative controls for FAKSOR 
demonstrated a decreased fluorescence lifetime with FI-14 at 3.2 ns (Fig. 3h; 3.2 ns) and the 
mutant FAKSOR at 2.9 ns (Fig. 3b, d, e, 3b; 2.9 ns).
Experiments show that FAKSOR exhibited a dose-dependent decrease in fluorescence 
lifetime upon inhibitor treatment (Fig. 3c–h, j). The histograms of average fluorescence 
lifetime of FAKSOR derived from approximately 50 cells for each condition (Fig. 3i) 
demonstrates that fluorescence lifetime of the labeled peptide biosensor increased by 12 % 
upon activation and found to be FAK phosphorylation dependent.
The difference in average fluorescence lifetimes between each treatment group was found to 
be statistically significant at α=0.05 (P <0.001). In addition to monitoring the temporal 
dynamics of the FAKSOR signal, distinct FAKSOR spatial profiles indicated its nuclear 
activation (Fig. 4a) after 15 minutes of stimulation with 20 ng/mL 1μM Angiotensin II.
Our findings are in concordance with the previous in vitro study on FAK nuclear localization 
and activation23. Quantitative analysis (Fig. 4c) confirmed that FAKSOR in ECFC treated 
with Angiotensin II (orange line) not only signals a higher average fluorescence than the 
control, but also experiences detectable changes in the initial average fluorescence lifetime 
(3.10 ns to 3.92 ns).
On the other hand, the control (green line) does not show any noticeable change in average 
lifetime over the 25-minute time course. This observation is representative of three technical 
and three independent biological replicates. For negative controls, real-time observations in 
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three different cells was also conducted for FAKSOR using FI-14, a FAK phosphorylation 
inhibitor, treatment. After a 25-minute treatment with FI-14, the fluorescence lifetime 
images of FAKSOR in ECFCs exhibited decreased fluorescence lifetime compared to the 
control (Fig. 4b).
Quantitative analysis (Fig. 4d) validated the FLIM observations of FAKSOR in ECFC 
treated with FI-14 (orange), not only had a lower fluorescence lifetime compared to control 
but also exhibited a detectable decrease from its initial average fluorescence lifetime (3.9 ns 
to 3.34 ns). On the other hand, the control did not show any noticeable decrease in average 
lifetime over the 25-minute time course (green line). Our observation represents three 
technical and three independent biological replicates.
Under the same experimental conditions, a similar trend was observed for hMSC (ESI Fig. 9 
a–c) and C2C12 (ESI Fig. 10a–c) cell types. Results from the positive and negative control 
demonstrated that the fluorescence lifetime of FAKSOR is phosphorylation and FAK kinase 
dependent and can be applied to a variety of cell types. After validating the performance of 
FAKSOR, we tested the sensors’ utility in a musculoskeletal cell line subjected to 
extracellular tension. The average fluorescence lifetime of FAKSOR was monitored in either 
bare culture flask or a PEG-based scaffold (ESI Fig. 10 a, b). FLIM images (ESI Fig. 10 a–
d) and quantitative analysis (ESI Fig. 10 e, f) show that internalized FAKSOR in the 
musculoskeletal cells exhibited higher average fluorescence lifetime, when the cells were 
grown on PEG (ESI Fig. 10b) compared to those grown on plastic (ESI Fig. 10 a). Our 
results suggest that scaffold materials induce higher activity of FAK phosphorylation in 
musculoskeletal cells. Interestingly, real time recording of the fluorescence lifetime of 
FAKSOR on the scaffold reveals dynamic phenotype-dependent FAK phosphorylation (ESI 
Fig. 10 c, d, f, ESI Video 1). Our results demonstrate the ability of FAKSORs to report on 
FAK phosphorylation dynamics in live cells when triggered by an external stimulus, in this 
case, tension from the scaffolds.
Herewith, we demonstrate an approach to monitor real time cellular FAK signaling in 
response to extracellular cues, specifically chemokines or extracellular (substrate) tension. 
The developed methodology encompassing a non-genetically encoded peptide biosensor 
with fluorescence lifetime imaging at singe molecule resolution presents a compelling 
approach for real time monitoring of FAK phosphorylation dynamics. Our platform captures 
the real-time dynamics of FAK activity, allowing spatiotemporal monitoring of signaling in 
response to stimuli. With appropriate choice of fluorophores more complex interactions 
between FAK and its downstream signaling partners could be explored in a multiplex 
format. The methodology developed can also be applied to monitor phosphorylation 
dynamics in 3D cultures as well as in vivo models.
METHODS
Detailed experiment procedure is available in the ESI
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Schematic for FAK phosphorylation monitoring in live cells with a peptide biosensor by 
FLIM
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Figure 2. 
Sensor design and evaluation. (a) Schematic depicts FAK FERM (Four-point- one-Ezrin-
Radixin-Moesin)-Kinase domain (blue) including the Tyr-397 auto-phosphorylation site 
(red). Our putative peptide sensor was designed by including Tyr-397 and its adjacent amino 
acids as the sensor recognition sequence (dark blue) conjugated with a TAT sequence, which 
enables live cell imaging and monitoring of phosphorylation. Fluorophore reporter, 5-FAM 
(Ex/Em, 492/518), was placed +2 amino acids from the Tyr-397 site. Mutant sensor was 
designed by replacing the tyrosine site with a phenylalanine (Y-F) (orange). (b) When 
FAKSOR is phosphorylated it exhibits a longer fluorescence decay (red) than the control 
mutant FAKSOR (orange) (c). Fluorescence lifetime images (d, e) of FAKSOR in 2D-
cultured ECFC after treatment with Angiotensin II (1 μM, 30 min) (d) demonstrates a higher 
average fluorescence lifetime (3.82 ns) compared to (e) non-phopshorylatable FAKSOR 
mutant (2.91 ns).
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Figure 3. 
FAKSOR fluorescence lifetime depends on FAK phosphorylation. (a–h) Fluorescence 
lifetime images for different treatments; For FAKSOR positive controls, Angiotensin II (1 
μM) was added to the medium (c) resulting in a higher average fluorescence lifetime (3.91 
ns) compared to control (a,3.54 ns) as well as the negative control mutant FAKSOR (b, 3.38 
ns). (d–h) Treatment with FI-14 (90 minutes), a Tyr397 inhibitor, decreased the average 
fluorescence lifetime of FAKSOR in a dose-dependent manner (d) 0.5 μM (3.78 ns), (e) 1 
μM (3.63 ns), (f) 3 μM (3.58 ns), (g) 5 μM (3.47 ns), (h) 10 μM (3.39 ns) (I,j) Quantitative 
analysis; (i) Fluorophore lifetime per cell calculated based on the average from at least 50 
cells in 3 replicates and, for each condition, and plotted as a distribution of observed 
lifetimes, (j) Quantitative analysis shows average fluorescence lifetime for different 
treatments (n=50).
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Figure 4. 
Real Time Fluorescence Lifetime Imaging of FAKSOR activity. (a), (b) Real time 
measurement of FAKSOR fluorescence lifetime in ECFC shows an increase (a) and decrease 
(b) of average florescence lifetime in (a) Angiotensin II- and (b) FI14-treated cells over a 25-
minute observation. (c) quantitative analysis reveals that treating ECFC with Angiotensin II 
(1μM) (orange line and dot) increases average fluorescence lifetime (3.92 ns from 3.10 ns) 
over 25 minutes, while controls do not show a change in average lifetime (green line and 
dot). (d) When ECFC are treated with FI14, FAKSOR average lifetime decreases over 25 
minutes (orange line and dot), while controls, again, did not experience a change in average 
fluorescence lifetime (green line with dot). Our observation is representative of three 
technical and three independent biological replicates.
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